Ann: Investor Product Demonstration, page-15

I disagree - just been on the video conference call. CLearly the new management team is highly capable and the business is building additional demand driven products that are fit for purpose for specific markets - eg aged care.

As others have posted, the share price was driven down by the absolutely awful Convertible Note Issue that was entered into in 2nd half of 2019. And that was after the miserable Medical Media acquisition..... the Board was asleep at the wheel and needs more commercially and strategically savvy directors.

The restructuring of the cost base of the company and the recent capital raising put the company in good stead for a recovery and a re-rating. If and when the CN parties sell the remainder of shares they acquired through conversion of the notes, there could well be a further re-rating.